,
Siviero, Paola http://orcid.org/0000-0001-6567-5808
Limongi, Federica
Gesmundo, Antonella
Zambon, Sabina
Cooper, Cyrus
Dennison, Elaine M.
Edwards, Mark H.
Timmermans, Erik J.
van der Pas, Suzan
Schaap, Laura A.
van Schoor, Natasja M.
Denkinger, Michael D.
Herbolsheimer, Florian
Peter, Richard
Castell, Maria Victoria
Otero, Ángel
Queipo, Rocio
Pedersen, Nancy L.
Deeg, Dorly J. H.
Maggi, Stefania
Article History
Received: 16 January 2019
Accepted: 26 April 2019
First Online: 17 May 2019
Ethics approval and consent to participate
: All the participants gave written informed consent and the study design and procedures, outlined in detail elsewhere [], were granted approval by local ethics committees (Germany: Universitat Ulm Ethikkommission [312/08]. Italy: Comitato Etico Provinciale Treviso [XLIV-RSA/AULSS7]. The Netherlands: Medisch Ethische Toetsingscommissie Vrije Universiteit Amsterdam [2002/141]. Spain: Comité Ético de Investigación Clínica del Hospital Universitario La Paz Madrid [PI-1080]. Sweden: Till forskningsetikkommittén vid Karolinska Instituted Stockholm [00–132]. UK: Hertfordshire Research Ethics Committee [10/H0311/59]).
: Not applicable.
: CC: consultancy, lecture fees and honoraria from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB (less than $ 10,000 each).ED: speaking fees from Eli Lilly (less than $ 10,000).No competing interests were reported by the other authors.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.